|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable (net of allowance for doubtful accounts of $285 and $75 as of December 31, 2019 and 2018, respectively) (a) | ||||||||||||||||||||
| Accounts receivable – affiliate | ||||||||||||||||||||
| Accounts receivable (net of allowance for credit losses of $3,047 and allowance for doubtful accounts of $285 as of March 31, 2020 and December 31, 2019, respectively) (a)(b) | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||
| Less: accumulated depreciation | ||||||||||||||||||||
| Net property, plant and equipment | ||||||||||||||||||||
| Investment in unconsolidated entity | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Net intangible assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Notes receivable from Equitrans Midstream (c) | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Due to Equitrans Midstream | ||||||||||||||||||||
| Credit facility borrowings | ||||||||||||||||||||
| Capital contributions payable to the MVP Joint Venture | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Credit facility borrowings | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Contract liability | ||||||||||||||||||||
| Regulatory and other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Predecessor equity | ||||||||||||||||||||
| Series A Preferred Units (24,605,291 units issued and outstanding at each of March 31, 2020 and December 31, 2019) | ||||||||||||||||||||
| Common and Class B | ||||||||||||||||||||
| Common Units | ||||||||||||||||||||
| Class B Units | ||||||||||||||||||||
| Total common and Class B | ||||||||||||||||||||
| General partner units (0 and 1,443,015 units issued and outstanding at December 31, 2019 and 2018, respectively) | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...